drugset / Trial / NCT05754684
Quadruple Immunotherapy for Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dinutuximab | Monoclonal antibody | — | Intravenous |
| Subject | Natural killer cell | Cell therapy | — | Intravenous |
| Subject | Naxitamab | Monoclonal antibody | — | Intravenous |
| Subject | Spironolactone | Small molecule | — | Oral |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |